All the news Showing 10 of 83 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NICE consults on draft guidance recommending ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C NICE / 04 March 2015 FDA revokes breakthrough status for BMS hep C drug Fierce Biotech / 11 February 2015 Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102 Achillion press release / 09 February 2015 European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C AbbVie press release / 16 January 2015 FDA declines to approve Bristol-Myers hepatitis drug Reuters / 27 November 2014 CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe AbbVie press release / 21 November 2014 Two studies show promise for 8-week treatment with GS-5816 Healio Hepatology / 17 November 2014 Merck’s four-week treatment for hepatitis C misses the mark Wall Street Journal / 11 November 2014 New pill that can cure hepatitis C approved for patients in Scotland STV / 11 November 2014 FDA approves first combination pill to treat hepatitis C FDA / 22 October 2014 ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive